ISM REPORT* & Market Turn Date!

DGLY mentioned above at $7 slipped through the cracks... I bought a small position for my wife and cleared it off my board and lost track of it-- of course it exploded $9. sloppy. I apologize. Should of given you all the heads up.~ stoney :eek:
 
Quote from stonedinvestor:

INTERESTING
STOCK &
MUSINGS
REPORT

Good day folks. I'm in a good mood the taxes came back from the accountant and I paid so much last year it's not so bad. I won't have to wreck whole portfolios or beg my mom for a loan. That's good. Let's talk about a couple things.... WARNING***** 4/10/08' is a super important CYCLE TURN DATE, so if you get my meaning, we better be drifting down before that day, god forbid we rally hard into 4/10... sell sell sell......

VIX is down, volume down, lets bring stocks down too in the next few days.... These are the interesting stocks now.

1. SWIM. I put out a help request on this name in a thread here on ET and got my usual nothing in response this is " Investools " and I'm sure a lot of you use it, the metrics, the numbers of accounts they seem good, stock is down a lot..... watch list material @ $11.

2. AGEN I'm going to do a whole wild world of biotech piece soon but this is the strangest case ever- a failed FDA event, a company that can't afford to go to new trials and instead turns to Russia who greenlights the worlds first cancer vaccine!... it's front page news in Russia; a strange, strange case, the first trial yields a mere 1.7 extra yrs survival; the new russia trial seems to indicate something better- an ability to attack clumpy tumors before they spread. An article is apparently coming soon in a peer journal... keep an eye on AGEN @ $2.90..

3. AMAG pharm... wow I recommended this stock at $50!!! It's a sad tale and a controversial ceo but it's also a big big product if they can ever get it to market
Merrrl killed them today and the stock is down big Jeffries though supported it with this- (NASDAQ:AMAG): Strongly believe Ferumoxytol will recieve first pass approval- Jefferies
Jefferies out on the box saying to buy AMAG. Analyst says there will be NO delay.
Jefferies notes on Friday they held a conference call for clients featuring AMAG CEO Dr. Brian Pereira. The firm says AMAG bears have argued that the ferumoxytol development program does not include a sufficient number of patient exposures to meet I.C.H safety guidelines (N=1,500). To set the record straight the firm notes, AMAG's CEO went on record (again) to confirm that, in total, over 1,700 patients and healthy volunteers were treated with ferumoxytol in the co's eleven clinical studies. The firm also says the fact that AMAG has the resources to execute additional clinical trials in C.K.D, but has chosen not to do so, suggests that AMAG strongly believes the filing is complete in its current form, per FDA guidance.

Could go either way i may place a bet here later today before Pfizer buys them.

4. IMMR is " buzzing " again wait for a pull in to $7 1/2 (hopefully over the next few days)

5. PTEC, I've profiled this stock a bit on ET, how can you be at a five year high boring ole' PTEC? Great little barrons mention- I tore it out, will read and redistribute later....

6. ADEP- this is a sleepy little robot company that doesn't trade enough shares to get me involved yet but how can you not notice that what was once simply medical applications has led to a slew of SOLAR POWER announcements, yup these nimble robots put together the panels too.... watch this one & let's get some more volume to it....

7. Delcath is my longest holding in my trading account. I've gone on a big ole' down slide with them and now am back UP- as a reader of all the endless studies I have never lost hope. Their tech is INGENIOUS IT REMOVES THE LIVER FROM THE BLOOD CIRCULATION DURING INTENSIVE CHEMO and the blood is purified before re entering the liver thus the toxins never make their way into the other areas of the body. Anyway a hedge fund got involved and took up all their money in a court fight and it's been a long hard road... the stock has been up SHARPLY LATELY and is up another 5% today... DCTH is that one I've married and may have to redo my nuptials again!

Delcath liver isolation device shows promise in cancer trial:

GET THE LATEST MARKET REPORTS

* Delcath Systems
* PHP
* cancer
* melphalan
* liver
09-Apr-2008 - US-based Delcath Systems has achieved positive results in treating diffuse liver cancer using its percutaneous hepatic perfusion (PHP) delivery system.
The chemotherapy agent melphalan was administered to 24 patients using the PHP delivery system in a Phase II clinical trial.

Only 19 of those receiving the drug could be fully evaluated, with a significant tumour reduction reported for two patients and a partial tumour reaction in a further 13 people.

This gave an objective tumour response of 79 per cent and Delcath has said it now plans to submit a new trial protocol to the US Food and Drug Administration (FDA) for the use of PHP as a first-line treatment for liver cancer.

Dr James Pingpank Jr, MD of the Surgery Branch of the National Cancer Institute in Bethesda, said: "The Delcath PHP System is unique in its ability to isolate then repeatedly treat unresectable liver tumours with high doses of anti-cancer agents such as melphalan.

"This study shows that PHP with melphalan has efficacy in patients with diffuse metastatic neuroendocrine tumors of the liver that are too extensive for resection, ablation, or embolization. Responses to therapy tend to be durable, and repeat therapy is effective on progression or recurrence of disease."

Speaking to in-PharmaTechnologist.com, CEO and president of Delcath Systems Richard Taney discussed the benefits of the PHP system.

He said: "As long as the patient is able to safely receive anesthesia or is healthy enough to receive systemic chemotherapy the procedure would not be too stressful for them.

"Most patients in our trials have been heavily pre-treated with a variety of regionalized and systemic therapies and had continued to show progression of disease prior to coming on trial."

The PHP delivery system isolates the liver from the rest of the body, allowing high drug doses to be administered, without the body suffering from the toxic effects of the chemotherapeutic agent.

This is achieved through the use of a double balloon catheter to block the inferior vena cava which normally drains the liver.

By doing this hepatic venous outflow is isolated and the blood diverted through a filtration system outside the body which removes the chemotherapeutic agent before returning the blood.

This reduces the body's exposure to the toxic effects of the chemotherapy by 80 to 90 per cent compared to hepatic artery infusion alone.

In doing so the PHP system seeks to protect the liver and the rest of the body from the harmful effects of the chemotherapeutic agents.

Taney said: "We have not seen toxicities to the healthy liver tissue with this procedure as blood flow to the liver is never stopped during this procedure and this is the case despite the high doses of melphalan.

"In the prior surgical isolation procedures in the 1990s they were using doses of melphalan that were three times higher than the normal systemic dose, they were seeing high levels of liver cell toxicities and the surgical procedure could be performed only once.

"The Delcath System administers doses seven times higher than the approved systemic dose, with no liver toxicities and is repeatable (has been done 10 times to a single patient)."

Melphalan has been delivered at a maximum dose of 3.5mg/kg and even then no liver toxicities were detected.

The dose is currently limited as the filtration system can remove only 80 to 85 per cent of the chemotherapeutic agent but will probably increase in the future as Delcath is currently investing heavily in filtration technology, according to Taney.

This improved filtration technology should prove beneficial for melphalan delivery, as well as the other agents Delcath envisage using PHP for.

So far two mainstay cancer drugs 5-FU and doxorubicin have also been tested on humans, with other agents in the pipeline.

back with more Interesting Stocks as they come up!
~stoney
More...

There is an inverse relationship between post length and usefulness.
 
Stoney just throws out a bunch of picks and some are right and some are wrong just like a coin flip. There was a portfolio of stocks posted this year by Stoney and each one is still deep in the red.

Im not saying Stoney isnt a nice likeable guy, but even a broken clock is right twice a day. Stoney needs to re-evaluate what he is doing and perform more research and write less creative diatribe.
 
Quote from Port1385:

Stoney just throws out a bunch of picks and some are right and some are wrong just like a coin flip. There was a portfolio of stocks posted this year by Stoney and each one is still deep in the red.

Im not saying Stoney isnt a nice likeable guy, but even a broken clock is right twice a day. Stoney needs to re-evaluate what he is doing and perform more research and write less creative diatribe.
More...

Yea he tends to recommend small obscure crappy stocks.
 
At first I wasn't going to reply for it was just the stocktrad3r and everyone knows about his ability to trade. now unfortunately I've got some newbie chirping along and lending advice with no hair on his balls.

because this is a widely read forum I will do this once and only once but YOU UNTHANKFULL BASTARDS IN THE LAST THREE WEEKS ALONE I HAVE GIVEN YOU ALL THE FOLOWING 30% PLUS GAINERS- FEED ITRN CBLI CRNT LF, CFSG, COIN (50%) then moving a little further out .... CSIQ YGE ENER SYNA CREE.... THATS FREAKIN 12 and I've only gotten to page 6 of my search function.... I could go on and on ...who's going to step to that?

You are holding me accountable to a new years thread that I have freely admitted got crushed with the 15% down move in small stocks and believe me,I felt that crush personally in my trading account... and yes I'm still striving to get back to even there.... but the art of investing is identifying small stocks and positions and moving them into large accounts when you become comfortable with them. Don't forget MLNM was a headliner in said portfolio....

I do so much damn research and heavy lifting compared to most posters here that to even insinuate I don't is irrational. And if you would like to step up and throw out TWELVE NAMES THAT EACH ARE GOING TO MOVE OVER 30% in a short period then, well feel free. I'm sure ET readers will appreciate that...

My eh in the middle not down or slightly up
MRVL hold CHINA hold JRJC out but watching
PANL can't remember think I own still in 1 acct.
CCC Hold.

The following stocks are my mistakes that i am still dealing with BGC sold. EMKR big holding
Tasr sold. AMSC. sold. MPEL. Sold. Seed Sold. YGE (on a downswing- sold.) Sigm Holding and KILLING ME... So you can see all is not static you two dolts. Before you pollute a beautiful thread again, think long and hard about your place, both in the universe and here at Elite Trader. ~ stoney
 
You must log in or register to reply here.
Back
Top